797 related articles for article (PubMed ID: 28984200)
1. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
Yang XH; Tang F; Shin J; Cunningham JM
BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
[TBL] [Abstract][Full Text] [Related]
2. A c-Myc-regulated stem cell-like signature in high-risk neuroblastoma: A systematic discovery (Target neuroblastoma ESC-like signature).
Yang XH; Tang F; Shin J; Cunningham JM
Sci Rep; 2017 Mar; 7(1):41. PubMed ID: 28246384
[TBL] [Abstract][Full Text] [Related]
3. PRC2-Mediated Transcriptomic Alterations at the Embryonic Stage Govern Tumorigenesis and Clinical Outcome in MYCN-Driven Neuroblastoma.
Tsubota S; Kishida S; Shimamura T; Ohira M; Yamashita S; Cao D; Kiyonari S; Ushijima T; Kadomatsu K
Cancer Res; 2017 Oct; 77(19):5259-5271. PubMed ID: 28807939
[TBL] [Abstract][Full Text] [Related]
4. FUBP1 promotes neuroblastoma proliferation via enhancing glycolysis-a new possible marker of malignancy for neuroblastoma.
Jiang P; Huang M; Qi W; Wang F; Yang T; Gao T; Luo C; Deng J; Yang Z; Zhou T; Zou Y; Gao G; Yang X
J Exp Clin Cancer Res; 2019 Sep; 38(1):400. PubMed ID: 31511046
[TBL] [Abstract][Full Text] [Related]
5. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
6. The PRC2 molecule EED is a target of epigenetic therapy for neuroblastoma.
Shaliman D; Takenobu H; Sugino RP; Ohira M; Kamijo T
Eur J Cell Biol; 2022; 101(3):151238. PubMed ID: 35636260
[TBL] [Abstract][Full Text] [Related]
7. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
8. The deubiquitinating enzyme UCHL1 is a favorable prognostic marker in neuroblastoma as it promotes neuronal differentiation.
Gu Y; Lv F; Xue M; Chen K; Cheng C; Ding X; Jin M; Xu G; Zhang Y; Wu Z; Zheng L; Wu Y
J Exp Clin Cancer Res; 2018 Oct; 37(1):258. PubMed ID: 30359286
[TBL] [Abstract][Full Text] [Related]
9. The growth-inhibitory Ndrg1 gene is a Myc negative target in human neuroblastomas and other cell types with overexpressed N- or c-myc.
Li J; Kretzner L
Mol Cell Biochem; 2003 Aug; 250(1-2):91-105. PubMed ID: 12962147
[TBL] [Abstract][Full Text] [Related]
10. Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma.
Ochiai H; Takenobu H; Nakagawa A; Yamaguchi Y; Kimura M; Ohira M; Okimoto Y; Fujimura Y; Koseki H; Kohno Y; Nakagawara A; Kamijo T
Oncogene; 2010 May; 29(18):2681-90. PubMed ID: 20190806
[TBL] [Abstract][Full Text] [Related]
11. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
12. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
[TBL] [Abstract][Full Text] [Related]
13. Integration of clinical characteristics and molecular signatures of the tumor microenvironment to predict the prognosis of neuroblastoma.
Cheng H; Zhang L; Yang S; Ren Q; Chang S; Jin Y; Mou W; Qin H; Yang W; Zhang X; Zhang W; Wang H
J Mol Med (Berl); 2023 Nov; 101(11):1421-1436. PubMed ID: 37712965
[TBL] [Abstract][Full Text] [Related]
14. EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.
Wang C; Liu Z; Woo CW; Li Z; Wang L; Wei JS; Marquez VE; Bates SE; Jin Q; Khan J; Ge K; Thiele CJ
Cancer Res; 2012 Jan; 72(1):315-24. PubMed ID: 22068036
[TBL] [Abstract][Full Text] [Related]
15. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
[TBL] [Abstract][Full Text] [Related]
16. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
[TBL] [Abstract][Full Text] [Related]
17.
Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
[TBL] [Abstract][Full Text] [Related]
18. The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.
Kim SH; Yang WI; Min YH; Ko YH; Yoon SO
Tumour Biol; 2016 Feb; 37(2):2037-47. PubMed ID: 26337274
[TBL] [Abstract][Full Text] [Related]
19. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
20. Unfavorable neuroblastoma prognostic factor NLRR2 inhibits cell differentiation by transcriptional induction through JNK pathway.
Sheikh A; Takatori A; Hossain MS; Hasan MK; Tagawa M; Nagase H; Nakagawara A
Cancer Sci; 2016 Sep; 107(9):1223-32. PubMed ID: 27357360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]